Skip to main content
Journal of Zhejiang University. Science. B logoLink to Journal of Zhejiang University. Science. B
. 2014 Aug;15(8):727–734. doi: 10.1631/jzus.B1300321

Identification of a novel mutation in a Chinese family with Nance-Horan syndrome by whole exome sequencing*

Nan Hong 1,§, Yan-hua Chen 1,§, Chen Xie 1, Bai-sheng Xu 1, Hui Huang 2, Xin Li 2, Yue-qing Yang 2, Ying-ping Huang 2, Jian-lian Deng 2, Ming Qi 2,3,4,†,, Yang-shun Gu 1,†,
PMCID: PMC4129093  PMID: 25091991

Abstract

Objective: Nance-Horan syndrome (NHS) is a rare X-linked disorder characterized by congenital nuclear cataracts, dental anomalies, and craniofacial dysmorphisms. Mental retardation was present in about 30% of the reported cases. The purpose of this study was to investigate the genetic and clinical features of NHS in a Chinese family. Methods: Whole exome sequencing analysis was performed on DNA from an affected male to scan for candidate mutations on the X-chromosome. Sanger sequencing was used to verify these candidate mutations in the whole family. Clinical and ophthalmological examinations were performed on all members of the family. Results: A combination of exome sequencing and Sanger sequencing revealed a nonsense mutation c.322G>T (E108X) in exon 1 of NHS gene, co-segregating with the disease in the family. The nonsense mutation led to the conversion of glutamic acid to a stop codon (E108X), resulting in truncation of the NHS protein. Multiple sequence alignments showed that codon 108, where the mutation (c.322G>T) occurred, was located within a phylogenetically conserved region. The clinical features in all affected males and female carriers are described in detail. Conclusions: We report a nonsense mutation c.322G>T (E108X) in a Chinese family with NHS. Our findings broaden the spectrum of NHS mutations and provide molecular insight into future NHS clinical genetic diagnosis.

Keywords: Nance-Horan syndrome (NHS), Exome sequencing, X-linked disorder

1. Introduction

Nance-Horan syndrome (NHS) (OMIM: 302350) is a rare X-linked syndrome, first reported in detail by Horan and Billson (1974) and Nance et al. (1974). Affected male patients often manifest bilateral congenital dense nuclear cataracts, characteristic dental anomalies, craniofacial abnormalities, and, in some cases, mental retardation (MR) (Toutain et al., 1997; Ding et al., 2009). Congenital dense nuclear cataracts in affected males usually lead to profound vision loss; thus, cataract surgery should be performed at an early age (Burdon et al., 2003). Other ophthalmological features include microcornea, microphthalmia, nystagmus, and strabismus. Dental abnormalities characteristic of NHS consist of screwdriver-shaped incisors, supernumerary maxillary incisors (mesiodens), and diastema (Walpole et al., 1990). Heterozygous females display similar, but milder clinical manifestations than affected males (Ding et al., 2009).

NHS is caused by mutations in the NHS gene, which comprises 10 coding exons and encodes at least 5 isoforms as a result of alternative splicing (Brooks et al., 2010). NHS-A and NHS-1A are two major isoforms of the NHS protein. The two isoforms are transcribed from exon 1 of the NHS gene, encoding a 1630-amino-acid protein and a 1651-amino-acid protein, respectively (Brooks et al., 2010). The NHS gene is expressed in the midbrain, lens, tooth, retina, and dental primordia, in a spatially and temporally regulated pattern, and is highly conserved across vertebrate species, such as mouse, rat, and zebrafish (Huang et al., 2007; Sharma et al., 2008).

To date, approximately 27 mutations in the NHS gene have been identified (Burdon et al., 2003; Brooks et al., 2004; Ramprasad et al., 2005; Florijn et al., 2006; Huang et al., 2007; Sharma et al., 2008; Coccia et al., 2009; Chograni et al., 2011; Khan et al., 2012; Tug et al., 2013), including nonsense mutations, frameshift mutations, genomic rearrangements, and one missense mutation. In this study, we identified a novel nonsense mutation c.322G>T (E108X) in the NHS gene’s exon 1 in a family with NHS by a combination of exome sequencing and Sanger sequencing. The clinical features in all affected males and female carriers are described in detail.

2. Materials and methods

2.1. Subjects and ethics approval

This study followed the tenets of the Declaration of Helsinki and was approved by the Ethics Committee of the First Affiliated Hospital, School of Medicine, Zhejiang University, China. A three-generation family with congenital cataracts, microcornea, strabismus, and nystagmus was recruited. Seven members of the family participated in the study, three affected (II:1, II:2, and III:1) and four unaffected (I:1, I:2, I:3, and II:3) members. Informed consent and blood samples were obtained from all the participants in the family. All participants underwent comprehensive ophthalmological examinations including visual acuity, slit-lamp biomicroscopy, fundus examination, intraocular pressure (IOP) measurement, and IOLMaster testing. Nonocular features related to NHS were also noted. A total of 50 healthy individuals without congenital ocular diseases were selected serving as an ethnically-matched control. Genomic DNA was extracted using the QIAamp DNA Blood Midi kit (Qiagen, Hilden, Germany), according to the manufacturer’s protocol.

2.2. Exome sequencing

One affected male (III:1) in the family was selected for exome sequencing. Exome sequencing was carried out using the Agilent SureSelect Human All Exon v4.0 (51M) kit, according to the manufacturer’s protocol. The 3 μg of genomic deoxyribonucleic acid (DNA) was randomly fragmented into pieces 200–300 bp in size using a Covaris acoustic system, followed by end-repair, A-tailing, and Covaris acoustic measurements. The adapter-ligated templates were purified using Agencourt AMPure SPRI beads and amplified by four-cycle ligation-mediated polymerase chain reaction (LM-PCR), under the following PCR condition: 2 min at 94 °C, four cycles of 10 s at 94 °C, 30 s at 62 °C, and 30 s at 72 °C, then 300 s at 72 °C. The LM-PCR products were hybridized to the Agilent Oligo pool for enrichment for 24 h at 65 °C. Hybridized fragments were bound to streptavidin beads and non-hybridized fragments were washed out. Captured LM-PCR products were amplified by PCR (2 min at 98 °C; 10–12 cycles for 10 s at 98 °C, 30 s at 60 °C, 30 s at 72 °C, followed by 300 s at 72 °C). The magnitude of enrichment of the samples was estimated with an Agilent 2100 bioanalyzer and quantitative PCR. The captured library was sequenced on Illumina HiSeq2000 analyzers for 90 cycles per read, to generate paired-end reads and 8 bp of the index tag (following the manufacturer’s standard sequencing protocols).

2.3. Mapping, single-nucleotide polymorphism (SNP), and insertion and deletion (InDel) calling

Image analysis and base calling were performed according to the Illumina pipeline. Indexed primers were used for data fidelity surveillance. Short Oligonucleotide Analysis Package (SOAP) aligner (Ver. 2.21) was used to map the clean reads to the human reference genome (hg19) with a maximum fault-tolerance of 3-bp mismatches. Based on these results, the SOAPsnp software (Ver. 1.05) was used to assemble the consensus sequence and call genotypes in target regions. Candidate single-nucleotide SNPs were selected using the following criteria: SNP quality ≥20, sequencing depth ≥4-fold, estimated copy number ≤2, and distance between two SNPs >5 bp. For small InDels <20 bp in exome regions, we mapped the reads to the reference genome with the Burrows Wheeler Aligner (BWA; Ver. 0.6.2), and passed the result to the Genome Analysis Tool kit (GATK) to identify breakpoints.

2.4. PCR and Sanger sequencing

Following the results of exome sequencing, Sanger sequencing was performed to verify the genetic defects. Primers flanking the mutation area of NHS (NM_198270) were designed, based on the reference genomic sequences of the human genome from GenBank at the National Center for Biological Information (NCBI), and synthesized by Invitrogen, Shanghai, China. The forward primer was 5'-TTCGCCAAGCGGATCGTGGA-3', and the reverse primer was 5'-TTAGGGTCAAGCGTGCTGAGGA-3'. PCR amplification was carried out using an Applied Biosystems Inc. (ABI) 9700 Thermal Cycler. PCR products were directly sequenced on an ABI PRISM 3730 automated sequencer (Applied Biosystems). Sequence data comparisons and analyses were performed using DNASTAR SeqMan. Co-segregation analysis was subsequently performed on the DNA samples from available family members.

2.5. Bioinformatics analysis

Multiple sequence alignment of NHS protein sequences from Homo sapiens (GenPept accession NP_938011.1), Mus musculus (GenPept accession NP_001074521.1), Bos taurus (GenPept accession NP_001192657.1), Macaca mulatta (GenPept accession XP_001104229.2), Canis lupus familiaris (GenPept accession XP_548877.2), Sus scrofa (GenPept accession XP_005673517.1), and Equus caballus (GenPept accession XP_005614077.1) was performed using CLC Sequence Viewer 5.5 (CLC bio A/S, http://www.clcbio.com).

3. Results

3.1. Clinical features

The family included three affected members (II:1, II:2, and III:1), all males. A male in the third generation was adopted at birth and lost contact with other members of the family. Information on this male member was missing (Fig. 1a). We suggest that the mode of inheritance of the pedigree was X-linked or autosomal.

Fig. 1.

Fig. 1

Pedigree structure and patient phenotypes of the family

(a) Pedigree of a family with Nance-Horan syndrome (NHS). The male identified by a question mark may have been affected, and was adopted out of the family. (b) A photograph of an affected male (III:1) showing a long and narrow face, broad base to the nose, and a thin nasal bridge. (c) Screwdriver-shaped incisors and diastema in individual III:1. The right incisor of the patient was broken in his childhood. (d) Slit-lamp photograph of a carrier female (II:3) showing lens opacities in the posterior Y-suture and cortical coralliform opacity in the left eye. (e, f) Bitemporal retraction in two female carriers (II:3 and I:1)

A detailed description of clinical features is given in Table 1. All affected males had received bilateral lensectomy at an early age to remove congenital nuclear cataracts. All presented with bilateral microcornea, nystagmus, and strabismus. Individual III:1 (Fig. 1b) exhibited typical NHS dental anomalies (screwdriver-shaped left incisor and diastema, and the right incisor of the patient was broken in childhood, as shown in Fig. 1c), which were not noted in the other two affected males. All affected males had the same craniofacial dysmorphisms (a long, narrow face with a broad base to the nose and a thin nasal bridge). Other nonocular anomalies, such as MR, brachymetacarpalia, or cardiovascular abnormalities, were not observed in these three males.

Table 1.

Clinical features of the affected males and the female carriers in the NHS family

Subject Eye BSCVA Ocular feature Dental anomaly Craniofacial dysmorphism
Male patients
II:1 OD 20/400 Underwent bilateral lensectomy due to congenital nuclear cataract, bilateral microcornea, strabismus, and nystagmus Screwdriver-shaped left incisor* and diastema Long and narrow face, broad base to nose, and thin nasal bridge
OS 20/160
II:2 OD 20/400 Underwent bilateral lensectomy due to congenital nuclear cataract, bilateral microcornea, strabismus, and nystagmus Long and narrow face, broad base to nose, and thin nasal bridge
OS 20/160
III:1 OD 20/120 Underwent bilateral lensectomy due to congenital nuclear cataract, bilateral microcornea, strabismus, and nystagmus Long and narrow face, broad base to nose, and thin nasal bridge
OS 20/120

Female carriers
I:1 OD 20/60 Opacities in the Y-suture and cortex of the lens in both eyes Bitemporal retraction
OS 20/40
II:3 OD 20/20 Lens opacities in the posterior Y-suture Bitemporal retraction
OS 20/30 Lens opacities in the posterior Y-suture and cortical coralliform opacity

BSCVA: best spectacle corrected visual acuity; OD: the right eye; OS: the left eye

*

The right incisor of the patient was broken in his childhood

Carrier female II:3 had bilateral fine white dots in the Y-suture of the lenses and a prominent white coralliform cortical opacity in the inferior part of the lens in the left eye (Fig. 1d). Individual I:1 exhibited cortical opacities in both eyes. The two females exhibited bitemporal retraction (Figs. 1e and 1f). No other symptoms related to NHS were observed in the two carrier females.

3.2. Exome sequencing

Using the Agilent SureSelect capture system and the bioinformatics pipeline described in Section 2.5, a mean depth of 84-fold was obtained for this sample, and 95.03% of the target exome region was covered at least 20-fold, indicating that sufficient coverage was achieved for variant calling (Table 2). In total, 103 897 single nucleotide variants (SNVs) and 11 656 small InDels were detected (Table 3). Variants leading to protein coding changes, including missense, nonsense, readthrough, and small InDel variants in the coding region, and potential splice site variants (±10 bp of coding sequence (CDS)), were picked first. Then we used ‘1000 Genome’ data, dbSNP, and the HapMap database to filter out polymorphism variants. Variants with a frequency >0.01 in any of these three databases were filtered out. As a result, we identified 1268 rare variants in the affected male. We first screened these variants for inheritance in an X-linked manner and identified 12 variants on the X chromosome (Table 4). Then, we searched for mutations of known genes involved in hereditary cataracts by visual inspection. The variant c.322G>T in the NHS gene was identified as a candidate mutation.

Table 2.

Sequencing quality statistics of exome capture for the proband sample (individual III:1)

Parameter Value
Total target exome region (bp) 51 391 525
Raw reads 93 225 420
Raw data yield (Mb) 8390
Reads mapped to genome 72 489 626
Reads mapped to target region1 55 230 353 (59.24%)
Data mapped to target region (Mb) 4316.82 (51.45%)
Capture specificity2 (%) 76.82
Mean depth of target region (fold) 84
Mean depth of chromosome X (fold) 48.24
Mean depth of chromosome Y (fold) 48.37
Rate of nucleotide mismatch (%) 0.17
Fraction of target covered (%)
 ≥4-fold 99.42
 ≥10-fold 98.32
 ≥20-fold 95.03
1

Reads mapped to target regions are reads that are within or overlap with the target region

2

Capture specificity is defined as the percentage of uniquely mapped reads aligning to the target region

Table 3.

Variant statistics of exome capture sequencing for the proband sample (individual III:1) and variant filter statistics

Parameter Number
SNV InDel
 Total 103 897 11 656
 Alt_start 14
 Synonymous 12 519
 Missense 8124
 Nonsense 60
 Readthrough 4
 Frameshift 92
 Inframe 232
 Splice 2299 362
 Intron 65 274 8979
 5-UTR 1928 205
 3-UTR 4136 588
 Intergenic 9539 1198
 Hom 42 783 5148
 Het 61 114 6508

Total (SNVs+InDels) 115 553
Variants leading to protein coding change 11 187
Rare variants leading to protein coding change 1268
Rare variants in chromosome X 12
Rare variants in NHS gene 1

SNV: single nucleotide variant; InDel: insertion and deletion; Alt_start: start codon change to an alternative start codon, which can be considered as a start codon coding-synonym; UTR: untranslated regions; Hom: homozygous; Het: heterozygous

Table 4.

Rare variants leading to protein coding changes on the chromosome X

Gene Function Variant Frequency
rs ID
dbSNP 1000 Genome HapMap
CXorf59 Missense c.1267C>G
CXorf59 Frameshift c.1267_1268insTG
EDA2R Missense c.323C>T 0.001 rs186691097
GPR112 Inframe c.7966_7968delGAT
IL13RA2 Missense c.907C>A
MAP3K15 Splice c.3567-8delT
NHS Nonsense c.322G>T
NUDT11 Splice c.1_−1_13delGCTGCCTCGAGGA
PRDX4 Splice c.242-10 A>T 0.001 rs513572
TEX11 Splice c.1202-4delT
ZBTB33 Inframe c.563_564insTGA
ZNF182 Missense c.282C>A 0.006 0.0065 rs150066211

rs ID: reference SNP ID number

3.3. NHS mutation analysis and bioinformatics analysis

A previously undescribed nonsense mutation, c.322G>T, in exon 1 of the NHS gene (NM_198270), was identified in the three affected males and in the two carrier females (Fig. 2), but was not detected in the unaffected males or normal controls. This mutation resulted in conversion of glutamic acid to a stop codon at position 108 (E108X). The mutation was not documented in any current database (1000 Genomes Project or HapMap), indicating that the mutation was unlikely to represent an SNP. Multiple sequence alignments were performed and we observed that codon 108, where the mutation (c.322G>T) occurred, was located within a phylogenetically conserved region (Fig. 3).

Fig. 2.

Fig. 2

DNA sequence chromatograms

A nonsense mutation in exon 1, c.322G>T, resulting in E108X in the three affected males and two female carriers, and the normal sequence from two unaffected males

Fig. 3.

Fig. 3

Multiple-sequence alignment of NHS from different species

Multiple-sequence alignment of NHS from different species revealed that codon 108, where the mutation (E108X) occurred, was located within a highly conserved region

4. Discussion

In the present study, we characterized a Chinese family with NHS. Molecular genetic analysis identified a novel nonsense mutation c.322G>T (E108X) in exon 1 of the NHS gene in all affected males and carrier females. The mutation was not detected in unaffected males or in normal controls. This substitution was conserved in seven tested species, confirming it as a co-segregating disease-causing mutation in the family.

NHS is a rare X-linked disorder, usually underdiagnosed by ophthalmologists with subtle nonocular manifestations that are easily overlooked (Ding et al., 2009). The affected males in the Chinese family presented with congenital dense cataract, microcornea, nystagmus, and strabismus; nonocular symptoms were not investigated at the initial meeting. We performed exome sequencing of DNA from an affected male (III:1) and identified a mutation in the NHS gene, which was then shown to segregate with the phenotype in the pedigree. After identification of the mutation, we recalled the family to examine the pedigree members comprehensively. All three affected males manifested craniofacial dysmorphisms characteristic of NHS. Individual III:1 (Fig. 1b) also exhibited typical NHS dental anomalies (screwdriver-shaped incisors and diastema). Among the heterozygous females, carrier signs of NHS were also detected, including lens opacities in the posterior Y-sutures and subtle craniofacial dysmorphism (bitemporal retraction). All of the observations indicated the presence of an NHS phenotype in the family, consistent with the results of the molecular genetic analysis.

NHS is a syndrome with high phenotypic heterogeneity. Tug et al. (2013) summarized the phenotypes of patients with different mutations and found no obvious genotype-phenotype correlations between the position of each mutation and clinical severity. In our study, nonocular features among the members of the family were also not identical; for example, dental anomalies were observed only in individual III:1 (Fig. 1b). The phenotypic heterogeneity may be due to the role of modifier genes in nonocular tissues (Sharma et al., 2006).

The exact biological function and structure of the NHS protein remain unclear. On the basis of position-specific iterated BLAST (PSI-BLAST) analysis, Huang et al. (2006) reported that the N-terminus of the mouse Nhs1 protein contained a poly-proline domain and a Wiskott-Aldrich syndrome protein (WASP) homology 1 (WH1) domain. Both of these domains are known to be related to targeting proteins to the cytoskeleton. Evidence from a study of Brooks et al. (2010) showed that the N-termini of isoforms NHS-1A and NHS-A contain a WASP family verprolin-homologous (WAVE) domain (WHD), functionally homologous to the WHD in WAVE proteins. This can interact with members of the Abelson-interactor (Abi) protein family, such as Abi1 and Abi2, playing a regulatory role in actin remodelling and maintaining cell morphology.

In the present study, we describe the first Chinese case of NHS caused by a nonsense mutation in the NHS gene. The mutation (c.322G>T) induces a putative premature stop codon at nucleotide 322 (E108X), producing a truncated NHS protein. The abnormal protein may initiate the nonsense-mediated mRNA decay (NMD) pathway, a well-known translation-coupled quality control system that degrades mutant mRNA containing premature termination codons (PTCs) (Khajavi et al., 2006). NMD can protect cells from the toxic effects of truncated proteins caused by dominant-negative or gain-of-function effects (Khajavi et al., 2006). Previously, Ramprasad et al. (2005) performed reverse transcription-PCR (RT-PCR) on DNA samples from an Indian NHS family with the c.115C>T (Q39X) mutation in exon 1 of the NHS gene and found no evidence of NMD.

It has been reported that some mRNAs harbouring PTCs located in some specific regions can avoid the NMD pathway, leading to the translation of abnormal mRNAs (Khajavi et al., 2006). If the mRNA containing the c.322G>T (E108X) mutation in the present study escaped from the NMD pathway, amounts of truncated protein with possibly destructive effects would be produced in cells. Also, the E108X mutation may damage the function of the WHD of the NHS protein, for example by disrupting the interaction between the WHD and some other functional protein, resulting in an NHS phenotype in patients. However, the pathogenic mechanism of NHS should be investigated in depth in future.

In summary, we identified a novel nonsense mutation (c.322G>T) in exon 1 of the NHS gene in a Chinese family, which leads to the conversion of glutamic acid to a stop codon (E108X). Our study shows that whole exome analysis in a single affected male from a family exhibiting X-linked inheritance could be used efficiently to identify causative mutations on the chromosome X, thus providing help to clinicians in making a definitive diagnosis of rare diseases.

Acknowledgments

We greatly appreciate the invaluable cooperation and participation of the family members in the present study.

Footnotes

*

Project supported by the Science and Technology Specific Project of Zhejiang Province (No. 2009C03010-2), China

Compliance with ethics guidelines: Nan HONG, Yan-hua CHEN, Chen XIE, Bai-sheng XU, Hui HUANG, Xin LI, Yue-qing YANG, Ying-ping HUANG, Jian-lian DENG, Ming QI, and Yang-shun GU declare that they have no conflict of interest.

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for inclusion in the study. Additional informed consent was obtained from all patients for the use of identifying information included in this article.

References

  • 1.Brooks SP, Ebenezer ND, Poopalasundaram S, et al. Identification of the gene for Nance-Horan syndrome (NHS) J Med Genet. 2004;41(10):768–771. doi: 10.1136/jmg.2004.022517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Brooks SP, Coccia M, Tang HR, et al. The Nance-Horan syndrome protein encodes a functional wave homology domain (WHD) and is important for co-ordinating actin remodelling and maintaining cell morphology. Hum Mol Genet. 2010;19(12):2421–2432. doi: 10.1093/hmg/ddq125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Burdon KP, Mckay JD, Sale MM, et al. Mutations in a novel gene, NHS, cause the pleiotropic effects of Nance-Horan syndrome, including severe congenital cataract, dental anomalies, and mental retardation. Am J Hum Genet. 2003;73(5):1120–1130. doi: 10.1086/379381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Chograni M, Rejeb I, Jemaa LB, et al. The first missense mutation of NHS gene in a Tunisian family with clinical features of NHS syndrome including cardiac anomaly. Eur J Hum Genet. 2011;19(8):851–856. doi: 10.1038/ejhg.2011.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Coccia M, Brooks SP, Webb TR, et al. X-linked cataract and Nance-Horan syndrome are allelic disorders. Hum Mol Genet. 2009;18(14):2643–2655. doi: 10.1093/hmg/ddp206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Ding X, Patel M, Herzlich AA, et al. Ophthalmic pathology of Nance-Horan syndrome: case report and review of the literature. Ophthalmic Genet. 2009;30(3):127–135. doi: 10.1080/13816810902822021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Florijn RJ, Loves W, Maillette de Buy Wenniger-Prick LJ, et al. New mutations in the NHS gene in Nance-Horan syndrome families from the Netherlands. Eur J Hum Genet. 2006;14(9):986–990. doi: 10.1038/sj.ejhg.5201671. [DOI] [PubMed] [Google Scholar]
  • 8.Horan MB, Billson FA. X-linked cataract and Hutchinsonian teeth. Aust Paediatr J. 1974;10(2):98–102. [Google Scholar]
  • 9.Huang KM, Wu J, Duncan MK, et al. Xcat, a novel mouse model for Nance-Horan syndrome inhibits expression of the cytoplasmic-targeted Nhs1 isoform. Hum Mol Genet. 2006;15(2):319–327. doi: 10.1093/hmg/ddi449. [DOI] [PubMed] [Google Scholar]
  • 10.Huang KM, Wu J, Brooks SP, et al. Identification of three novel NHS mutations in families with Nance-Horan syndrome. Mol Vis. 2007;13:470–474. [PMC free article] [PubMed] [Google Scholar]
  • 11.Khajavi M, Inoue K, Lupski JR. Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease. Eur J Hum Genet. 2006;14(10):1074–1081. doi: 10.1038/sj.ejhg.5201649. [DOI] [PubMed] [Google Scholar]
  • 12.Khan AO, Aldahmesh MA, Mohamed JY, et al. Phenotype-genotype correlation in potential female carriers of X-linked developmental cataract (Nance-Horan syndrome) Ophthalmic Genet. 2012;33(2):89–95. doi: 10.3109/13816810.2011.634881. [DOI] [PubMed] [Google Scholar]
  • 13.Nance WE, Warburg M, Bixler D, et al. Congenital X-linked cataract, dental anomalies and brachymetacarpalia. Birth Defects Orig Artic Ser. 1974;10(4):285–291. [PubMed] [Google Scholar]
  • 14.Ramprasad VL, Thool A, Murugan S, et al. Truncating mutation in the NHS gene: phenotypic heterogeneity of Nance-Horan syndrome in an Asian Indian family. Invest Ophthalmol Vis Sci. 2005;46(1):17–23. doi: 10.1167/iovs.04-0477. [DOI] [PubMed] [Google Scholar]
  • 15.Sharma S, Ang SL, Shaw M, et al. Nance-Horan syndrome protein, NHS, associates with epithelial cell junctions. Hum Mol Genet. 2006;15(12):1972–1983. doi: 10.1093/hmg/ddl120. [DOI] [PubMed] [Google Scholar]
  • 16.Sharma S, Burdon KP, Dave A, et al. Novel causative mutations in patients with Nance-Horan syndrome and altered localization of the mutant NHS-A protein isoform. Mol Vis. 2008;14:1856–1864. [PMC free article] [PubMed] [Google Scholar]
  • 17.Toutain A, Ayrault AD, Moraine C. Mental retardation in Nance-Horan syndrome: clinical and neuropsychological assessment in four families. Am J Med Genet. 1997;71(3):305–314. doi: 10.1002/(SICI)1096-8628(19970822)71:3&#x0003c;305::AID-AJMG11&#x0003e;3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]
  • 18.Tug E, Dilek NF, Javadiyan S, et al. A Turkish family with Nance-Horan syndrome due to a novel mutation. Gene. 2013;525(1):141–145. doi: 10.1016/j.gene.2013.03.094. [DOI] [PubMed] [Google Scholar]
  • 19.Walpole IR, Hockey A, Nicoll A. The Nance-Horan syndrome. J Med Genet. 1990;27(10):632–634. doi: 10.1136/jmg.27.10.632. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Zhejiang University. Science. B are provided here courtesy of Zhejiang University Press

RESOURCES